Corrigendum to "Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results" [Eur. J. Cardiothorac. Surg. 33 (2008) 531-536] (DOI:10.1016/j.ejcts.2007.12.019);Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results

European Journal of Cardio-thoracic Surgery

Volumn 33, Issue 4, 2008, Pages 531-536

  Colli, Andrea ^a   Verhoye, Jean Philippe ^b   Heijmen, Robin ^c   Strauch, Justus Thomas ^d   Hyde, Jonathan A J ^e   Pagano, Domenico ^f   Antunes, Manuel ^g   Koertke, Heinrich ^h   Ohri, Sunil Kumar ⁱ   Bail, Dorothee Helene Lina ^j   Leprince, Pascal ^k   Van Straten, Bart H M ^l   Gherli, Tiziano ^m  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITÉ DE RENNES 1   (France)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY OF COLOGNE   (Germany)

^e ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l CATHARINA HOSPITAL   (Netherlands)

^m UNIVERSITY OF PARMA   (Italy)

more..

Author keywords

Acetyl salicylic acid; Anticoagulants; Antiplatelet drugs; Antithrombotic therapy; Aortic bioprosthetic valve

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K;

ANTICOAGULATION TREATMENT INFLUENCE ON POSTOPERATIVE PATIENT REGISTRY; AORTA VALVE REPLACEMENT; ARTICLE; ASIA; BIOPROSTHESIS; BIOPROSTHETIC AORTIC VALVE REPLACEMENT; CANADA; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; EUROPE; HEALTH CENTER; HEALTH SURVEY; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; MIDDLE EAST; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REGISTER; THROMBOEMBOLISM;

EID: 40649114712     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.05.002     Document Type: Erratum

References (24)

1. Bonow R.O., Carabello B., de Leon Jr. A.C., Faxon D.P., Freed M.D., Gaasch W.H., Lytle B.W., Nishimura R.A., O'Gara P.T., O'Rourke R.A., Otto C.M., Shah P.M., Shanewise J.S., Smith Jr. S.C., Jacobs A.K., Adams C.D., Anderson J.L., Antman E.M., Fuster V., Halperin J.L., Hiratzka L.F., Hunt S.A., Lytle B.W., Nishimura R., Page R.L., and Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 48 (2006) 598-675
2. Vahanian A., Baumgartner H., Bax J., Butchart E., Dion R., Filippatos G., Flachskampf F., Hall R., lung B., Kasprzak J., Nataf P., Tornos P., Torracca L., Wenink A., Priori S.G., Blanc J.J., Budaj A., Camm J., Dean V., Deckers J., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Tamargo J., Zamorano J.L., Zamorano J.L., Angelini A., Antunes M., Fernandez M.A., Gohlke-Baerwolf C., Habib G., McMurray J., Otto C., Pierard L., Pomar J.L., Prendergast B., Rosenhek R., Uva M.S., and Tamargo J. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28 (2007) 230-268
3. Salem D.N., Stein P.D., Al-Ahmad A., Bussey H.I., Horstkotte D., Miller N., and Pauker S.G. Antithrombotic therapy in valvular heart disease - native and prosthetic: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 3 Suppl. (2004) 457S-482S
4. Jamieson W.R., Cartier C.P., and Allard M. Surgical management of valvular heart disease. Can J Cardiol 20 Suppl. E (2004) 15
5. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998;101:374-87.
6. LeGuyader A., Watanabe R., Berbé J., Boumediene A., Cogné M., and Laskar M. Platelet activation after aortic prosthetic valve surgery. Interactive Cardiovasc Thorac Surg 5 (2006) 60-64
7. Chesebro J.H., Adams P.C., and Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 8 Suppl. B (1986) 41B-56B
8. Dewanjee M.K., Trastek V.F., Tago M., and Kaye M.P. Radioisotopic techniques for noninvasive detection of platelet deposition in bovine-tissue mitral-valve prostheses and in vitro quantification of visceral microembolism in dogs. Invest Radiol 19 (1984) 535-542
9. Harker L.A., and Slichter S.J. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 283 (1970) 1302-1305
10. Stein B., Fuster V., Halperin J.L., and Chesebro J.H. Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. Circulation 80 (1989) 1501-1513
11. Nemerson Y., and Turitto V.T. The effect of flow on hemostasis and thrombosis. Thromb Haemost 66 (1991) 272-276
12. Pengo V., Peruzzi P., Baca M., Marzari A., Zanon F., Schivapappa L., and Dalla Volta S. The optimal therapeutic range for oral anticoagulant treatment as suggested by fibrinopeptide A (FpA) levels in patients with heart valve prostheses. Eur J Clin Invest 19 (1989) 181-184
13. Brais M., and Braunwald N.S. Acceleration of tissue in-growth on materials implanted in the heart. Ann Thorac Surg 21 (1976) 221-229
14. Bull B., and Braunwald N.S. Human histopathologic response to a completely fabric-covered prosthetic heart valve. Ann Surg 174 (1971) 755-761
15. Heras M., Chesebro J.H., Fuster V., Penny W.J., Grill D.E., Bailey K.R., Danielson G.K., Orszulak T.A., Pluth J.R., Puga F.J., Schaff H.V., and Larsonkeller J.J. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25 (1995) 1111-1119
16. Blair K.L., Hatton A.C., White D.W., Blair K.L., Hatton A.C., White W.D., Smith L.R., Lowe J.E., Wolfe W.G., Young W.G., Oldham H.N., Douglas Jr. J.M., and Glower D.D. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation 90 5 Pt 2 (1994) II214-II219
17. Kulik A., Rubens F.D., Mesana T.G., and Lam B.K. Early postoperative anticoagulation: more questions than answers?. Ann Thorac Surg 82 (2006) 1573-1574
18. Bonow R.O., Carabello B., de Leon Jr. A.C., Edmunds Jr. L.H., Fedderly B.J., Freed M.D., Gaasch W.H., McKay C.R., Nishimura R.A., O'Gara P.T., O'Rourke R.A., Rahimtoola S.H., Ritchie J.L., Cheitlin M.D., Eagle K.A., Gardner T.J., Garson Jr. A., Gibbons R.J., Russell R.O., Ryan T.J., and Smith Jr. S.C. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Circulation 98 (1998) 1949-1984
19. Stein P.D., Alpert J.S., Bussey H.I., Dalen J.E., and Turpie A.G.G. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119 1 Suppl. (2001) 220S-227S
20. Vaughan P., and Waterworth P.D. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair. J Heart Valve Dis 14 (2005) 576-582
21. Brueck M., Kramer W., Vogt P., Steinert N., Roth P., Gorlach G., Schonburg M., and Heidt M.C. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg 32 (2007) 108-112
22. di Marco F., Grendene S., Feltrin G., Meneghetti D., and Gerosa G. Antiplatelet therapy in patients receiving aortic bioprostheses: a report of clinical and instrumental safety. J Thorac Cardiovasc Surg 133 (2007) 1597-1603
23. Nowell J., Wilton E., Markus H., and Jahangiri M. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg 31 (2007) 578-585
24. Colli A., Verhoye J.P., Leguerrier A., and Gherli T. Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue. Eur J Cardiothorac Surg 31 (2007) 573-577